In hospitalized individuals with a confirmed diagnosis of severe COVID-19, aspirin administration is beneficial and is linked with a remarkable drop in the mortality rate, as elucidated from a retrospective cohort study published in The Journal of Medical Virology. Researchers investigated the effect of aspirin add-on therapy on the outcome of individuals hospitalized due to severe or critical coronavirus infection.

Recording of demographics and associated clinical data during their hospitalization was done. The major endpoint was the mortality rate of patients, while the requirement for mechanical ventilation and duration of hospitalization were the secondary endpoints. The study incorporated 991 participants (544 males, 447 females). Notably, 34% (336/991) of participants were given aspirin during their hospital admission, and 66% (655/991) of participants did not receive aspirin.

A raised prevalence of comorbidities was witnessed in people who were given aspirin. As per the multivariate COX proportional model, a considerable independent association was noted between aspirin use and a decline in the risk of in-hospital mortality (Hazard ratio 0.746 [0.560-0.994]). Additional prospective and robust randomized controlled trials are required for exploring the efficacy and side effects of aspirin administration in COVID-19 people.